131 related articles for article (PubMed ID: 10918315)
1. Initial measurements of ifosfamide and cyclophosphamide in patients using (31)P MRS: pulse-and-acquire, decoupling, and polarization transfer.
Payne GS; Pinkerton CR; Bouffet E; Leach MO
Magn Reson Med; 2000 Aug; 44(2):180-4. PubMed ID: 10918315
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide versus ifosfamide: to use ifosfamide or not to use, that is the three-dimensional question.
Williams ML; Wainer IW
Curr Pharm Des; 1999 Aug; 5(8):665-72. PubMed ID: 10469897
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide pharmacokinetics and hepatobiliary uptake in vivo investigated using single- and double-resonance 31P MRS.
Mancini L; Payne GS; Dzik-Jurasz AS; Leach MO
Magn Reson Med; 2003 Aug; 50(2):249-55. PubMed ID: 12876700
[TBL] [Abstract][Full Text] [Related]
4. Safe decontamination of cytostatics from the nitrogen mustards family. Part one: cyclophosphamide and ifosfamide.
Štenglová Netíková IR; Petruželka L; Šťastný M; Štengl V
Int J Nanomedicine; 2018; 13():7971-7985. PubMed ID: 30538471
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
Jounaidi Y; Chen CS; Veal GJ; Waxman DJ
Mol Cancer Ther; 2006 Mar; 5(3):541-55. PubMed ID: 16546968
[TBL] [Abstract][Full Text] [Related]
6. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and pharmacokinetics of oxazaphosphorines.
Boddy AV; Yule SM
Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
[TBL] [Abstract][Full Text] [Related]
8. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
[TBL] [Abstract][Full Text] [Related]
9. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.
Huang Z; Roy P; Waxman DJ
Biochem Pharmacol; 2000 Apr; 59(8):961-72. PubMed ID: 10692561
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
11. Introducing ifosfamide in innovative treatment modalities.
Dittrich C
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S1-3. PubMed ID: 12042981
[No Abstract] [Full Text] [Related]
12. Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide.
Sun L; Chen CS; Waxman DJ; Liu H; Halpert JR; Kumar S
Arch Biochem Biophys; 2007 Feb; 458(2):167-74. PubMed ID: 17254539
[TBL] [Abstract][Full Text] [Related]
13. Identification of biliary metabolites of ifosfamide using 31P magnetic resonance spectroscopy and mass spectrometry.
Payne GS; Dzik-Jurasz AS; Mancini L; Nutley B; Raynaud F; Leach MO
Cancer Chemother Pharmacol; 2005 Oct; 56(4):409-14. PubMed ID: 15877229
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide. Metabolic studies, new therapeutic approaches and new analogs.
Misiura K
Mini Rev Med Chem; 2006 Apr; 6(4):395-400. PubMed ID: 16613576
[TBL] [Abstract][Full Text] [Related]
15. Tandem mass spectrometric analysis of cyclophosphamide, ifosfamide and their metabolites.
Liu Z; Chan KK; Wang JJ
Rapid Commun Mass Spectrom; 2005; 19(18):2581-90. PubMed ID: 16106352
[TBL] [Abstract][Full Text] [Related]
16. Compatibility of palonosetron with cyclophosphamide and with ifosfamide during simulated Y-site administration.
Xu QA; Trissel LA
Am J Health Syst Pharm; 2005 Oct; 62(19):1998-2000. PubMed ID: 16174835
[TBL] [Abstract][Full Text] [Related]
17. Studies on the side-chain hydroxylation of ifosfamide and its bromo analogue.
Misiura K; Kinas RW; Kuśnierczyk H
Bioorg Med Chem Lett; 2002 Feb; 12(3):427-31. PubMed ID: 11814813
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide in the treatment of breast cancer.
Overmoyer BA
Semin Oncol; 1996 Jun; 23(3 Suppl 6):38-41. PubMed ID: 8677447
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide: let's not end the honeymoon too soon.
Chang AY
J Clin Oncol; 1995 Jul; 13(7):1824-6. PubMed ID: 7677853
[No Abstract] [Full Text] [Related]
20. Chemical degradation of wastes of antineoplastic agents: cyclophosphamide, ifosfamide and melphalan.
Hansel S; Castegnaro M; Sportouch MH; De Méo M; Milhavet JC; Laget M; Duménil G
Int Arch Occup Environ Health; 1997; 69(2):109-14. PubMed ID: 9001917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
